These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 17585312)

  • 1. Intravitreal triamcinolone and bevacizumab combination therapy for macular edema due to central retinal vein occlusion refractory to either treatment alone.
    Ekdawi NS; Bakri SJ
    Eye (Lond); 2007 Aug; 21(8):1128-30. PubMed ID: 17585312
    [No Abstract]   [Full Text] [Related]  

  • 2. Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion.
    Hu YJ
    Eye (Lond); 2010 Aug; 24(8):1414; author reply 1414-5. PubMed ID: 20339391
    [No Abstract]   [Full Text] [Related]  

  • 3. Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion.
    Tao Y; Hou J; Jiang YR; Li XX; Jonas JB
    Eye (Lond); 2010 May; 24(5):810-5. PubMed ID: 19696805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion.
    Cheng KC; Wu WC; Chen KJ
    Eye (Lond); 2009 Nov; 23(11):2023-33. PubMed ID: 19798117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion.
    Cekiç O; Cakır M; Yazıcı AT; Alagöz N; Bozkurt E; Faruk Yılmaz O
    Curr Eye Res; 2010 Oct; 35(10):925-9. PubMed ID: 20858114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of intravitreal bevacizumab for resistant macular edema due to central retinal vein occlusion after failure of intravitreal triamcinolone acetonide].
    Le Moigne O; Duncombe A; Portmann A; Muraine M; Genevois O
    J Fr Ophtalmol; 2012 Nov; 35(9):700-4. PubMed ID: 22925843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rebound of macular edema after intravitreal bevacizumab therapy in eyes with macular edema secondary to branch retinal vein occlusion.
    Yasuda S; Kondo M; Kachi S; Ito Y; Terui T; Ueno S; Terasaki H
    Retina; 2011 Jun; 31(6):1075-82. PubMed ID: 21478810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bilateral simultaneous intravitreal injections in the office setting.
    Bakri SJ; Risco M; Edwards AO; Pulido JS
    Am J Ophthalmol; 2009 Jul; 148(1):66-9.e1. PubMed ID: 19403114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular oedema.
    Synek S; Vojniković B
    Coll Antropol; 2010 Apr; 34 Suppl 2():99-103. PubMed ID: 21305729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion:results after 12 months and multiple regression analysis.
    Kondo M; Kondo N; Ito Y; Kachi S; Kikuchi M; Yasuma TR; Ota I; Kensaku M; Terasaki H
    Retina; 2009 Oct; 29(9):1242-8. PubMed ID: 19672216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months.
    Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
    Retina; 2010; 30(7):1002-11. PubMed ID: 20616679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial.
    Prager F; Michels S; Kriechbaum K; Georgopoulos M; Funk M; Geitzenauer W; Polak K; Schmidt-Erfurth U
    Br J Ophthalmol; 2009 Apr; 93(4):452-6. PubMed ID: 19074916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion.
    Rosenfeld PJ; Fung AE; Puliafito CA
    Ophthalmic Surg Lasers Imaging; 2005; 36(4):336-9. PubMed ID: 16156153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of central retinal vein occlusion-related macular edema with intravitreal bevacizumab (Avastin): preliminary results.
    Pournaras JA; Nguyen C; Vaudaux JD; Konstantinidis L; Ambresin A; Wolfensberger T
    Klin Monbl Augenheilkd; 2008 May; 225(5):397-400. PubMed ID: 18454380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of bevacizumab and triamcinolone for treatment of macular edema secondary to central retinal vein occlusion--a matched-pairs analysis.
    Guthoff R; Meigen T; Hennemann K; Schrader W
    Ophthalmologica; 2010; 224(2):126-32. PubMed ID: 19738392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up.
    Wu L; Arevalo JF; Roca JA; Maia M; Berrocal MH; Rodriguez FJ; Evans T; Costa RA; Cardillo J;
    Retina; 2008 Feb; 28(2):212-9. PubMed ID: 18301025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months.
    Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
    Retina; 2009; 29(10):1396-403. PubMed ID: 19898177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of intravitreal bevacizumab (IVB) in treating macular edema secondary to branch retinal vein occlusion (BRVO).
    Wong I; Koo S; Chan C
    Retina; 2010 Apr; 30(4):710; author reply 710-1. PubMed ID: 20386100
    [No Abstract]   [Full Text] [Related]  

  • 20. Early intravitreal bevacizumab for non-ischaemic central retinal vein occlusion.
    Rensch F; Jonas JB; Spandau UH
    Acta Ophthalmol; 2009 Feb; 87(1):77-81. PubMed ID: 18937800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.